| 26.5 0.68 (2.63%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.86 |
1-year : | 37.21 |
| Resists | First : | 27.28 |
Second : | 31.86 |
| Pivot price | 26.3 |
|||
| Supports | First : | 25.96 |
Second : | 25.15 |
| MAs | MA(5) : | 25.95 |
MA(20) : | 26.14 |
| MA(100) : | 27.38  |
MA(250) : | 26.49 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.6 |
D(3) : | 37.1 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 32.18 | Low : | 21.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PHG ] has closed below upper band by 40.5%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.76 - 26.89 | 26.89 - 27.01 |
| Low: | 25.93 - 26.08 | 26.08 - 26.22 |
| Close: | 26.26 - 26.49 | 26.49 - 26.7 |
Koninklijke Philips N.V. (PHG) functions as a prominent health technology enterprise, with its operations spanning across North America and numerous international markets. The company's diverse activities are organized into three primary business divisions: Diagnosis & Treatment, Connected Care, and Personal Health. Within its Diagnosis & Treatment segment, Philips delivers advanced diagnostic imaging solutions, which include magnetic resonance imaging (MRI), computed tomography (CT) systems, X-ray apparatus, and spectral CT technology based on detector platforms. This division also provides molecular and hybrid imaging capabilities crucial for nuclear medicine. Furthermore, it offers integrated systems for interventional procedures, along with ultrasound (echography) solutions specifically designed for diagnosis, treatment planning, and guidance in fields such as cardiology, general imaging, obstetrics/gynecology, and point-of-care applications. Complementing these are proprietary software tools for diagnostic and interventional support, alongside comprehensive enterprise diagnostic informatics products and associated services. The Connected Care division focuses on providing solutions for acute patient management, emergency care services, and specialized offerings for sleep and respiratory conditions. This also encompasses electronic medical record (EMR) systems and broader care management platforms. Meanwhile, the Personal Health segment caters to consumer well-being with products such as electric toothbrushes, replacement brush heads, interdental cleaning aids, and teeth whitening kits. It also manufactures infant feeding products and digital parental support tools, in addition to a range of male grooming and beauty products. Philips has forged significant strategic alliances, notably a collaboration with Ibex Medical Analytics Ltd. This partnership aims to jointly promote digital pathology and AI-driven solutions to hospitals, healthcare networks, and pathology laboratories worldwide. The company also maintains a key partnership agreement with NICO.LAB. Established in 1891, the company was initially known as Koninklijke Philips Electronics N.V. before officially rebranding as Koninklijke Philips N.V. in May 2013. Its corporate headquarters are located in Amsterdam, the Netherlands.
Tue, 09 Jun 2026
Doctors using AI treat more patients and catch more errors, Philips finds - Stock Titan
Mon, 08 Jun 2026
Koninklijke Philips N.V (PHG) Q4 2008 Earnings Call Transcript - MLQ.ai
Mon, 08 Jun 2026
Koninklijke Philips N.V. (PHG) Stock Analysis: A 28% Upside In The Healthcare Sector? - DirectorsTalk Interviews
Sun, 07 Jun 2026
PHG Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 03 Jun 2026
Here's Why Royal Philips (PHG) is a Strong Value Stock - Yahoo Finance
Tue, 02 Jun 2026
Philips (NYSE: PHG) sets 2025 dividend share exchange ratio - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 952 (M) |
| Shares Float | 951 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 1,860 (K) |
| Shares Short P.Month | 2,030 (K) |
| EPS | 1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.92 |
| Profit Margin | 5.5 % |
| Operating Margin | 6.1 % |
| Return on Assets (ttm) | 3.4 % |
| Return on Equity (ttm) | 8.3 % |
| Qtrly Rev. Growth | -4.7 % |
| Gross Profit (p.s.) | 8.37 |
| Sales Per Share | 18.52 |
| EBITDA (p.s.) | 2.19 |
| Qtrly Earnings Growth | 97.1 % |
| Operating Cash Flow | 2,290 (M) |
| Levered Free Cash Flow | 1,520 (M) |
| PE Ratio | 22.84 |
| PEG Ratio | 0.3 |
| Price to Book value | 1.9 |
| Price to Sales | 1.43 |
| Price to Cash Flow | 11.01 |
| Dividend | 1 |
| Forward Dividend | 0 |
| Dividend Yield | 3.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|